Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IDYA with free AI briefings, catalyst countdowns, and dilution alerts.

IDYA · IDEAYA Biosciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.2B Cash on Hand
38mo Cash Runway
Follow IDYA by email Get an email when IDYA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IDYA, unsubscribe in one click. Privacy

📣 What IDYA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Darovasertib (IDE196) Uveal Melanoma Phase 3 · NCT07015190 Recruiting
PD1 Inhibitor Neoplasms, Colorectal Phase 1/2 · NCT06710847 Active not recruiting
Anti-DLL3 Antibody-drug Conjugate IDE849 Small-cell Lung Cancer Phase 1/2 · NCT07174583 Recruiting
PARG Inhibitor IDE161 Small-cell Lung Cancer Phase 1/2 · NCT07174583 Recruiting
WRN Inhibitor GSK4418959 Neoplasms, Colorectal Phase 1/2 · NCT06710847 Active not recruiting
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific… Esophageal Squamous Cell Carcinoma Phase 1 · NCT07503808 Recruiting
Tuvutromstat (IDE397) Solid Tumor Phase 1 · NCT04794699 Active not recruiting
KAT6/KAT7 Inhibitor IDE574 Cancer Phase 1 · NCT07540572 Recruiting
PRMT5 Inhibitor IDE892 NSCLC Adenocarcinoma Phase 1 · NCT07277413 Recruiting

Also used in these trials (approved or third-party drugs, not IDYA's own candidates): Pembrolizumab, Crizotinib, Dacarbazine, Nivolumab, Ipilimumab, Carboplatin, Durvalumab, Binimetinib, Fulvestrant, Sacituzumab Govitecan.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IDYA holds $1.2B in cash and short-term investments (as of Sep 30, 2026) and burns about $90.8M/quarter from operations, an estimated runway of 38 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 32 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IDYA files for a raise →

👥 Who Owns IDYA

Insiders 0.9% Institutions (409 holders) 99.1% Public and other holders 0%
HolderTypeShares% of sharesAs of
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 7,265,253 7.51% 2026-03-31
Capital Research Global Investors Institution (13G, 5%+) 5,279,675 5.46% 2025-12-31
Baker Bros. Advisors LP Institution (13G, 5%+) 5,010,030 5.18% 2026-06-30
Vanguard Capital Management Institution (13G, 5%+) 4,834,771 5.00% 2026-06-30
Yujiro S Hata
President and CEO, Director · +1.41M options
Insider 690,695 0.71% 2026-10-06
Jason Throne
Chief Legal Officer · +42,546 options
Insider 63,484 0.07% 2024-06-27
Jeffrey Stein
Director · +56,200 options
Insider 57,644 0.06% 2026-03-02
Briseno Andres Ruiz
Chief Accounting Officer · +174,200 options
Insider 26,466 0.03% 2026-07-07
Douglas B. Snyder
SVP, General Counsel · +303,000 options
Insider 2,080 0.00% 2026-01-30

Share count 96,694,575 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IDYA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IDYA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.